The new 32mg tablet for oral suspension marks the first FDA-approved drug for pediatric PAH. The Food and Drug Administration (FDA) has approved a new strength of Tracleer (bosentan; Actelion) tablet ...
BASEL, Switzerland (Reuters) - Approval of Actelion Ltd's Tracleer for use in a fatal lung disease could double sales of its biggest drug, the biotech company's chief executive told Reuters. Actelion, ...
WASHINGTON, March 5 (Reuters) - Two Johnson & Johnson (JNJ.N), opens new tab units have agreed to pay $65 million to settle a proposed antitrust class action by health plans and others claiming they ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
The primary endpoint was to demonstrate that Tracleer prolonged the time to first morbidity or mortality event in patients with symptomatic PAH already receiving Revatio. Tracleer showed a risk ...
Actelion, the Swiss pharmaceutical company, is upbeat this week on news that its dual endothelin receptor antagonist Tracleer (bosentan) significantly improves pulmonary vascular resistance in ...
Johnson & Johnson (JNJ) subsidiaries Actelion Pharmaceuticals and Janssen Research & Development have agreed to pay $65M to settle a proposed antitrust class action suit related to J&J’s (JNJ) lung ...
Switzerland’s Actelion has posted a reasonable set of figures for the first nine months of 2009 as sales of its lead drug Tracleer continue to drive growth. Switzerland’s Actelion has posted a ...
Feb. 2, 2005 — The U.S. Food and Drug Administration (FDA) approved revisions to drug safety labeling last November, advising healthcare professionals of the following changes: use of ...
ALLSCHWIL, SWITZERLAND – November 20, 2001 -- Actelion Ltd. (SWX New Market: ATLN) today announced that the U.S. Food and Drug Administration (FDA) has approved Tracleer™ (bosentan), an orally active ...
To earn CME related to this news article, click here. This activity is part of an ongoing CME/CE initiative to provide information on labeling changes reported by the FDA. Activities of this nature ...
Hosted on MSN
Johnson & Johnson (JNJ) units to pay $65 million in Tracleer antitrust class action settlement, Reuters reports
Johnson & Johnson (NYSE:JNJ) is one of the top stocks that will make you rich in 10 years. Reuters reported on March 5 that two Johnson & Johnson (NYSE:JNJ) units have agreed to pay $65 million for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results